Latest Articles

Publication Date
Bayer begins Phase III study with Mirena for nonatypical endometrial hyperplasia - Medical Dialogues

Bayer begins Phase III study with Mirena for nonatypical endometrial hyperplasia Medical Dialogues

Published: Dec. 2, 2025, 5 a.m.
High inhibition ratio and transformation index of 2 mg dienogest: further evidence for its use in endometriosis treatment.

Endometriosis is a common, chronic disease with a high burden for women, characterised by the implantation of endometrial cells outside the uterus. Many different treatments have been proposed for this …

Published: Dec. 2, 2025, midnight
Histomorphometric characterization of the endometrium in mules (Equus mulus): An approach to endometritis/endometrosis.

Mules (Equus mulus), as sterile hybrids between mares and donkeys, present a unique uterine morphology and physiology that remains poorly characterized. This study provides the first histomorphometric evaluation and transcriptional …

Published: Dec. 2, 2025, midnight
GSK’s Jemperli now standard in endometrial cancer as reimbursement expands to 1st-line therapy - koreabiomed.com

GSK’s Jemperli now standard in endometrial cancer as reimbursement expands to 1st-line therapy koreabiomed.com

Published: Dec. 1, 2025, 6:49 a.m.
ZMIZ1 and estrogen receptor α form an essential partnership in endometrial biology.

Estrogen receptor α (ESR1) is a pivotal regulator of endometrial homeostasis and reproductive function, yet the coregulators that fine tune its transcriptional activity remain incompletely defined. In this issue of …

Published: Dec. 1, 2025, midnight
Transcriptional coregulator ZMIZ1 modulates estrogen responses that are essential for healthy endometrial function.

Estrogen is a critical regulator of endometrial health. Aberrant estrogen stimulation can result in infertility, endometrial cancer, and endometriosis. Here, we identified Zinc Finger MIZ-Type Containing 1 (Zmiz1) as a …

Published: Dec. 1, 2025, midnight
Dissecting endometrial cancer complexity in response to standard and targeted therapies - Nature

Dissecting endometrial cancer complexity in response to standard and targeted therapies Nature

Published: Nov. 28, 2025, 5:08 p.m.
Exploring the combined antiproliferative effects of artesunate and resveratrol in Ishikawa endometrial cancer cells - News-Medical

Exploring the combined antiproliferative effects of artesunate and resveratrol in Ishikawa endometrial cancer cells News-Medical

Published: Nov. 27, 2025, 10:29 a.m.
Impact of pelvic endometriosis on the chances of pregnancy in the context of oocyte donation.

Endometriosis is diagnosed in 25% to 40% of infertile patients. This disease can affect ovarian reserve and oocyte quality, as a result Assisted Reproductive Technology is often required. However, the …

Published: Nov. 27, 2025, midnight
DESTINY-Endometrial01 Will Examine T-DXd Plus Rilvegostomig or Pembrolizumab in HER2+ pMMR Endometrial Cancer - OncLive

DESTINY-Endometrial01 Will Examine T-DXd Plus Rilvegostomig or Pembrolizumab in HER2+ pMMR Endometrial Cancer OncLive

Published: Nov. 26, 2025, 7:03 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!